SiBone (NASDAQ:SIBN) Insider Anshul Maheshwari Sells 3,318 Shares of Company Stock

Key Points

• SiBone insider Anshul Maheshwari sold 3,318 shares at an average price of $18.18, generating $60,321.24. The sale covered tax-withholding obligations tied to vested equity awards, and reduced his direct ownership by 1.49% to 219,966 shares.
• SiBone shares recently traded down 1.3% to $19.55, but remain above their 50-day and 200-day moving averages. The company exceeded quarterly earnings and revenue expectations, reporting a loss of $0.09 per share on $56.01 million in revenue.
• Wall Street maintains a generally positive view, with six Buy ratings and one Sell rating and a consensus price target of $24.17. Institutional investors own approximately 98.11% of the stock.

SiBone (NASDAQ:SIBN - Get Free Report) insider Anshul Maheshwari sold 3,318 shares of the firm's stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $18.18, for a total value of $60,321.24. Following the sale, the insider directly owned 219,966 shares in the company, valued at approximately $3,998,981.88. This represents a 1.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Anshul Maheshwari also recently made the following trade(s):

• On Monday, October 5th, Anshul Maheshwari sold 1,731 shares of SiBone stock. The stock was sold at an average price of $19.50, for a total value of $33,754.50.
• On Monday, August 24th, Anshul Maheshwari sold 11,636 shares of SiBone stock. The stock was sold at an average price of $20.11, for a total transaction of $233,999.96.
• On Friday, August 21st, Anshul Maheshwari sold 11,228 shares of SiBone stock. The shares were sold at an average price of $20.02, for a total value of $224,784.56.
• On Wednesday, August 19th, Anshul Maheshwari sold 5,747 shares of SiBone stock. The stock was sold at an average price of $19.55, for a total transaction of $112,353.85.
• On Monday, August 17th, Anshul Maheshwari sold 4,665 shares of SiBone stock. The shares were sold at an average price of $18.65, for a total value of $87,002.25.

SiBone Trading Down 1.3%

Shares of SIBN stock traded down $0.26 on Tuesday, reaching $19.55. 538,730 shares of the company's stock were exchanged, compared to its average volume of 582,763. The company's fifty day simple moving average is $18.77 and its 200 day simple moving average is $16.20. SiBone has a 52 week low of $11.48 and a 52 week high of $21.89. The company has a current ratio of 9.15, a quick ratio of 7.55 and a debt-to-equity ratio of 0.20. The stock has a market capitalization of $867.04 million, a PE ratio of -57.50 and a beta of 0.66.

SiBone (NASDAQ:SIBN - Get Free Report) last released its earnings results on Monday, August 3rd. The company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.06. The business had revenue of $56.01 million for the quarter, compared to analyst estimates of $55.34 million. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%. As a group, analysts forecast that SiBone will post -0.4 EPS for the current year.

Institutional Investors Weigh In On SiBone

A number of hedge funds have recently made changes to their positions in the stock. Dimensional Fund Advisors LP lifted its position in shares of SiBone by 41.8% during the first quarter. Dimensional Fund Advisors LP now owns 618,939 shares of the company's stock valued at $7,816,000 after buying an additional 182,465 shares during the last quarter. First Light Asset Management LLC raised its stake in shares of SiBone by 51.8% during the 2nd quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company's stock worth $132,649,000 after acquiring an additional 2,774,795 shares in the last quarter. Next Century Growth Investors LLC lifted its position in SiBone by 508.4% during the fourth quarter. Next Century Growth Investors LLC now owns 141,998 shares of the company's stock valued at $2,800,000 after acquiring an additional 118,657 shares during the last quarter. Renaissance Technologies LLC boosted its stake in SiBone by 101.6% in the first quarter. Renaissance Technologies LLC now owns 472,619 shares of the company's stock valued at $5,969,000 after acquiring an additional 238,219 shares in the last quarter. Finally, Squarepoint Ops LLC grew its holdings in SiBone by 40.3% in the second quarter. Squarepoint Ops LLC now owns 118,128 shares of the company's stock worth $1,928,000 after purchasing an additional 33,947 shares during the last quarter. 98.11% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

SIBN has been the subject of a number of research reports. UBS Group boosted their price target on SiBone from $24.00 to $25.00 and gave the company a "buy" rating in a report on Tuesday, August 4th. TD Cowen raised their price objective on SiBone from $18.00 to $20.00 and gave the stock a "buy" rating in a report on Tuesday, August 4th. Weiss Ratings upgraded SiBone from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, August 20th. Finally, Truist Financial reissued a "buy" rating and set a $23.00 price target (up from $21.00) on shares of SiBone in a research report on Tuesday, August 4th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $24.17.

SiBone Company Profile

SI-BONE, Inc is a medical device company focused on developing and commercializing products for the surgical treatment of disorders affecting the sacroiliac joint, which connects the spine to the pelvis. The company's technology is intended to support minimally invasive procedures for patients with sacroiliac joint dysfunction and related conditions.

Its product portfolio includes the iFuse Implant System, a family of triangular titanium implants designed to stabilize and fuse the sacroiliac joint.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.